LONGEVITY & CELLULAR HEALTH / MATRIX
NAD+ and MOTS-c, Side by Side
Where the two cellular-energetics molecules converge, where they diverge, and how far the evidence behind each one actually reaches.
The short version
This page lines up NAD+ and MOTS-c on the dimensions that matter most when reading cellular-longevity research: what kind of molecule each one is, where it has been studied most, how strong that evidence is, how it was administered in studies, its regulatory standing, and its single biggest caution. The headline: both are studied through the lens of mitochondrial biology and metabolic aging, but they are at very different stages of human evidence. NAD+ precursors (NMN, NR) have multiple human RCTs demonstrating blood NAD+ elevation and, in some trials, metabolic effects — though translation to clinical longevity endpoints remains unresolved. MOTS-c has zero human interventional trials, with the strongest human signal being a biomarker association in a kidney-disease cohort. Neither is an approved medicine, and neither is presented here with a human dose.
The comparison matrix
| Dimension | NAD+ | MOTS-c |
|---|---|---|
| Molecule class | Endogenous redox coenzyme (dinucleotide); marketed as dietary supplement and IV wellness compound | Mitochondrial-derived peptide (MDP), 16 amino acids, encoded by mitochondrial DNA |
| Most-studied in | Energy metabolism, sirtuin/PARP/CD38 signaling, insulin sensitivity, cardiac function | Skeletal-muscle metabolism, exercise capacity, AMPK activation, aging in rodents |
| Evidence base (model) | Human RCTs for precursors (NMN, NR) raising blood NAD+; limited efficacy for hard endpoints [1] | Mostly mouse; one human biomarker cohort [9]; no human interventional trials |
| Administration studied | Oral precursor (NMN, NR) in humans; IV NAD+ (wellness); no approved injectables [2][5] | Subcutaneous/intraperitoneal injection in rodents; no human PK data [10] |
| Regulatory / WADA status | Not an approved drug; precursors sold as dietary supplements; NMN regulatory status contested; IV subject to recall | Not FDA-approved; WADA-prohibited (metabolic modulator) |
| Key caution | Blood NAD+ elevation consistent; translation to clinical outcomes inconsistent; 2025 review explicit on this [1] | No human interventional trials; rodent doses cannot be extrapolated; preclinical-only efficacy [10] |
Molecule class
The two molecules differ fundamentally in what they are. NAD+ is a coenzyme — a small organic molecule that enzymes require to function — not a peptide. It is found in every living cell and is the central electron carrier of metabolism. MOTS-c is a true peptide, 16 amino acids long, encoded within the mitochondrial genome rather than the nuclear genome. Both have roots in the mitochondrion — NAD+ is regenerated there by the electron transport chain, and MOTS-c is synthesized there and can translocate to the nucleus under stress [12] — but their molecular identities and mechanisms are entirely distinct.
Most-studied in
NAD+ research spans the widest territory: energy metabolism across tissues, sirtuin-mediated gene regulation, PARP-driven DNA repair, CD38-driven inflammatory aging, insulin sensitivity in skeletal muscle [3], and most recently cardiac ketogenesis and HFpEF [7]. MOTS-c research is more narrowly concentrated: skeletal-muscle glucose uptake and insulin sensitivity via AMPK, exercise capacity in aging rodents, nuclear stress-gene regulation via NRF2, and circulating biomarker associations in human disease cohorts [11][9].
Evidence base (model)
This is where the two most clearly separate. NAD+ precursors have been tested in multiple randomized human trials. A multicenter double-blind RCT of NMN in middle-aged adults showed dose-dependent blood NAD+ increases and improved walking distance at 60 days [2]. NR was dose-dependently raised blood NAD+ by 22-142% in a human placebo-controlled trial [5]. NMN improved muscle insulin sensitivity by hyperinsulinemic-euglycemic clamp in prediabetic women [3]. The 2025 Nature Metabolism review synthesizes this human base and finds consistent blood-level effects but limited clinical-endpoint efficacy [1].
MOTS-c has no comparable human intervention data. The strongest human signal is a cohort study showing lower circulating MOTS-c associates with higher mortality/cardiovascular risk in 94 hemodialysis patients — an observational association, not a demonstration that administering MOTS-c changes outcomes [9]. Mechanistic and efficacy data for exogenous MOTS-c come from animal models [8][11].
Administration studied
Routes reflect the research stage. NAD+ precursors are given orally in human trials — NMN at 250-900 mg/day [2][3], NR at 100-1,000 mg/day [5] — and blood NAD+ is the primary pharmacodynamic readout. IV NAD+ is used in wellness settings but has minimal controlled evidence. MOTS-c has been given by subcutaneous or intraperitoneal injection in animal studies at 0.5-15 mg/kg/day. No human pharmacokinetic study — measuring half-life, bioavailability, or dose-response — has been published for MOTS-c [10].
Regulatory and WADA status
Neither is an approved drug. NAD+ precursors are sold as dietary supplements, though NMN's supplement status has been challenged by the FDA (which has taken the position it may be excluded from the supplement category because it was previously investigated as a drug). Compounded injectable NAD+ has been subject to a Class I recall for endotoxin contamination. MOTS-c is not approved by the FDA for any use and is sold only as a research chemical. WADA prohibits MOTS-c at all times under metabolic-modulator categories; NAD+ and its precursors are not prohibited by WADA.
Key caution
Each molecule carries a defining caveat. For NAD+ the caution is the gap between a robust pharmacodynamic signal (blood NAD+ rises reliably) and validated clinical benefit — the 2025 Nature Metabolism review describes human efficacy data as limited and calls for more rigorous tissue-specific and outcome-focused trials [1]. For MOTS-c the caution is more fundamental: the entire efficacy literature is preclinical, rodent doses cannot be extrapolated to humans, and there are no human pharmacokinetic data on which to base any dosing rationale [10]. Reading them together, the consistent lesson is: a mechanistically coherent story and a demonstrated clinical benefit are two different things.